ReviewExpert opinion on emerging drugs2010
Emerging drugs for the treatment of symptoms associated with autism spectrum disorders.
Review in Expert opinion on emerging drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Cannabis and cannabinoid use in autism spectrum disorder: a systematic review.Trends in psychiatry and psychotherapy · 2022Pooled it
- Pharmacotherapy of restricted/repetitive behavior in autism spectrum disorder:a systematic review and meta-analysis.BMC psychiatry · 2020Pooled it
- Pharmacogenetics May Prevent Psychotropic Adverse Events in Autism Spectrum Disorder: An Observational Pilot Study.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Cannabis-Responsive Biomarkers: A Pharmacometabolomics-Based Application to Evaluate the Impact of Medical Cannabis Treatment on Children with Autism Spectrum Disorder.Cannabis and cannabinoid research · 2023Observational
- A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder.Experimental brain research · 2022Review
- Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report.Frontiers in pharmacology · 2022Article
- The Multi-Targeting Ligand ST-2223 with Histamine HInternational journal of molecular sciences · 2021Article
- Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders.Frontiers in pharmacology · 2020Review
- Pioglitazone abolishes cognition impairments as well as BDNF and neurotensin disturbances in a rat model of autism.Biology open · 2019Article
- Salivary biomarkers for the diagnosis and monitoring of neurological diseases.Biomedical journal · 2018Review
- Oral Cannabidiol Use in Children With Autism Spectrum Disorder to Treat Related Symptoms and Co-morbidities.Frontiers in pharmacology · 2018Article
- Article
- Prenatal exposure to TAK242 affects the childhood autism in offspring in animal models of autism spectrum disorder.Iranian journal of basic medical sciences · 2017Article
- Evidence of Mitochondrial Dysfunction in Autism: Biochemical Links, Genetic-Based Associations, and Non-Energy-Related Mechanisms.Oxidative medicine and cellular longevity · 2017Review
- Article
- Treatment for co-occurring attention deficit/hyperactivity disorder and autism spectrum disorder.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
importance of the fieldAutism spectrum disorders, or pervasive developmental disorders (PDDs), are neurodevelopmental disorders defined by qualitative impairment in social interaction, impaired communication and stereotyped patterns of behavior. The most common forms of PDD are autistic disorder (autism), Asperger's disorder and PDD not otherwise specified. Recent surveillance studies reveal an increase in the prevalence of autism and related PDDs. The use of pharmacologic agents in the treatment of these disorders can reduce the impact of interfering symptoms, providing relief for affected individuals and their families. AREAS COVERED IN THIS REVIEW: This review examines results from neurobiologic research in an attempt to both elucidate the pathophysiology of autism and guide the development of pharmacologic agents for the treatment of associated symptoms. The safety and efficacy data of drugs currently in clinical use for the treatment of these symptoms, as well as pharmaceuticals currently under development, are discussed. WHAT THE READER WILL GAIN: This comprehensive review will deepen the reader's current understanding of the research guiding the pharmacologic treatment of symptoms associated with autism and related PDDs. Areas of focus for future research are also discussed. The need for large-scale investigation of some commonly used pharmacologic agents, in addition to the development of drugs with improved efficacy and safety profiles, is made evident. TAKE HOME MESSAGE: Despite progress in the development of pharmacologic treatments for a number of interfering symptom domains associated with autism and other PDDs, a great deal of work remains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.